ltarol® Ophtha Abridged escribing Information

esentation: Sterile eye drop ution containing 0.1% (w/v) iofenac sodium in a servative free formulation single dose units.
s: Inhibition of operative miosis during aract surgery. Post-rative inflammation in ract surgery.
sage and Administration: *dts and Elderly:* phylaxis of peroperative osis: 1 drop four times ing the 2 hours prior to gery. Post-operative ammation: 1 drop four es daily for up to 10 days. *ldren:* Not established.
e: Each Voltarol Ophtha gle dose unit should be used a single dose only. (Discard ngle dose unit nediately after use.)
ntra-indications: ersensitivity to any of the edients. Like other AIDs, patients in whom cks of asthma, urticaria, or te rhinitis are precipitated etylsalicylic acid or by r drugs with prostaglandin thetase inhibiting activity. ocular use during surgical re.
cautions: In the presence nfection or risk of ction, appropriate therapy ntibiotic should be given currently with Voltarol tha. Use with caution in ents receiving other ications which may ong bleeding time, or with w haemostatic defects.
erse Reactions: Most uently, mild to moderate ning sensation. Rarely, red vision immediately instillation. ersensitivity reactions with ng and reddening, osensitivity, keratitis ata.
during pregnancy and ation: There is no rience concerning the of Voltarol Ophtha in an pregnancy or lactation. ministration is therefore not mmended except for celling reasons.
ity to drive and operate hinery: Patients with red vision should refrain driving a vehicle or ating machinery.
ributed by, and further rmation on request from: A Vision Ophthalmics, ge End, Southampton 3LG.
Holder: Ciba-Geigy plc. clesfield, Cheshire.
ge quantities and basic price: 4 x 0.3 ml SDUs 9, 40 x 0.3 ml SDUs 90 (PL 0001/172)
l Category: POM
notes registered trademark ba-Geigy
of preparation: October

IBAVision Ophthalmics

DH01/01/93

NEW *Voltarol®*
Ophtha SDUs ▼
diclofenac sodium solution 0.1% w/v

maintains mydriasis
controls post-cataract surgery inflammation

ANNOUNCING A FIRST



NOW two drops guard against the post-laser IOP spike

Iopidine ® is a selective alpha adrenergic agonist which helps to prevent acute postsurgical IOP elevations associated with Nd:YAG and argon laser surgery. [1-5]

PRESERVATIVE - FREE

Iopidine®▼

Apraclonidine Hydrochloride

OPHTHALMIC SOLUTION

Further information is available on request

Alcon Laboratories (UK) Ltd, Imperial Way,
Watford, Herts. WD2 4YR
Telephone: (0923) 246133 Fax: (0923) 243331

Alcon
SPECIALISTS IN EYE CARE

ABBREVIATED PRESCRIBING INFORMATION

Presentation: Each vial contains 0.25 ml of a sterile solution of 1.15% Apraclonidine Hydrochloride USP (equivalent to 1% w/v Apraclonidine base). **Indications:** Iopidine Ophthalmic Solution is indicated to control or prevent elevations in intraocular pressure following anterior segment laser surgery. **Dosage and Administration:** One drop instilled in the eye one hour before anterior segment laser surgery and one drop instilled in the same eye immediately upon completion of surgery. Iopidine is not recommended for use in children. No special precautions are required for dosage in the elderly. **Side Effects:** Iopidine is generally well tolerated. The most frequently reported side-effects include ocular injection (hyperaemia), lid retraction, conjunctival blanching and mydriasis. Although acute administration of Iopidine has been observed to have minimal effect on heart rate or blood pressure, there is a potential for systemic cardiovascular effects. **Precautions:** Caution should be observed in treating patients with severe cardiovascular disease, including hypertension. Clonidine-like drugs may cause drowsiness, affected patients should not drive or operate machinery. Pregnancy: Do not use unless the potential benefits outweigh the potential risks. Nursing mothers: It is not known whether Apraclonidine is excreted in human milk following ocular administration. Paediatric use: Iopidine is not recommended for use in children. **Contraindications:** Patients receiving monoamine oxidase inhibitor therapy, systemic sympathomimetic agents, tricyclic antidepressants and patients hypersensitive to this product. **Warnings:** Not for injection. Patients that develop exaggerated reduction in intraocular pressure should be closely monitored. **Legal Category:** POM **Package Quantities:** Two LDPE containers each containing 0.25 ml Iopidine Ophthalmic Solution are enclosed in a foil pouch and are presented in cartons of 12 pouches **Product Licence Number:** 0649/0120 **Basic NHS Price:** Carton of 12 pouches £84.00. **Product Licence Holder:** Alcon Laboratories (U.K.) Limited, Imperial Way, Watford, Hertfordshire. **Date of Preparation:** March 1993.

References:
1. Pollack IP, et al: Arch Ophthalmol 1988;106: 754-757. 2. Brown RH, et al: Ophthalmology 1988; 95: 378-384. 3. Robin AL, et al: Arch Ophthalmol 1987; 105: 646-650. 4. Robin AL, et al: Arch Ophthalmol 1987; 105: 1208-1211. 5. Data on file Alcon Laboratories (U.K. Ltd.